MONTREAL, CANADA–(Marketwired – May 1, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced today that Genesys Capital Management Inc. (“Genesys”) has been engaged to assist Knight with its business development efforts.

The mandate includes lending money on a secured basis to emerging biotechnology and specialty pharmaceutical companies in order to gain access to innovative products for the Canadian market.

When commenting on this agreement, Jonathan Ross Goodman, CEO of Knight, stated, “the relationship with Genesys is expected to generate incremental product opportunities for Knight within the first six months.”

Kelly Holman, managing partner at Genesys, said “we look forward to working closely with Knight to assist them in executing on their growth strategy.”

About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 and graduated to the TSX on April 29, 2014 under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company's web site at or at

About Genesys Capital Management Inc.:

Genesys Capital is one of the largest Canadian-based investors focused exclusively on the life sciences industry. For more information about Genesys Capital, please visit the Company's web site at

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company's final application for listing on the TSX Venture Exchange and can be found on SEDAR at, which investors should consult for additional information. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Neither TSX nor its Regulation Services Providers (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.